Open AccessmiR ‐21‐5p/ SMAD7 axis promotes the progress of lung cancer
Author(s) -
Tang Jinming,
Li Xu,
Cheng Tianli,
Wu Jie
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14060
Subject(s) - lung cancer , medicine , downregulation and upregulation , cell growth , cancer research , microrna , transfection , cancer , cell , cancer cell , cell culture , pathology , biology , gene , biochemistry , genetics
Background Lung cancer is one of the most common malignant tumors threatening human health. The aim of this study was to investigate the function of miR‐21‐5p in lung cancer progression. Methods We analyzed the expression levels of miR‐21‐5p in lung cancer tissues and cell lines. The qRT‐PCR and MTT assays were performed after transfection with miR‐21‐5p mimic, inhibitor and negative control into lung cancer cells. Results Luciferase reporter assays showed miR‐21‐5p directly target SMAD7. The miR‐21‐5p inhibitor significantly suppressed lung cancer cell proliferation, invasion and migration. We found that SMAD7 was upregulated in lung cancer tissue. In addition, we found that SMAD7 inhibited lung cancer cell proliferation and miR‐21‐5p mimic damaged the inhibitory effect of SMAD7. Conclusions miRNA‐21‐5p may promote cell proliferation, migration and invasion by spoiling SMAD7 expression in lung cancer cells.